Program
pelacarsen
Also written as “Pelacarsen”, “ISIS 681257” and “Pelacarsen (TQJ230)”.
Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Hyperlipoproteinemias · Acute Coronary Syndrome · Aortic Valve Stenosis, led by 2 companies.
Drug pagePelacarsen: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 104 open or running | phase 3since Jul 16, 2019 | Jul 16, 2019 | Feb 3, 2028phase 3 · NCT06813911 |
| Ionis Pharmaceuticalsits history only | 60 open or running | phase 2since Jan 31, 2017 | Apr 1, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Apr 1, 2015.
- Jul 16, 2019Novartis’s first study: phase 3 study in Cardiovascular DiseasesNew to NovartisNovartis · NCT04023552 · 8,323 enrolled · United States, Argentina, Australia and more
- Dec 9, 2019Named pelacarsenINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ISIS 681257, TQJ230
- Aug 4, 2021Phase 1 study in Hepatic ImpairmentNovartis · NCT05026996 · 17 enrolled · United States
- Mar 14, 2022Phase 3 study in Cardiovascular DiseasesNovartis · NCT05305664 · 51 enrolled · Germany
- Apr 13, 2022Phase 1 study in Healthy ParticipantsIonis Pharmaceuticals · NCT05337878 · 29 enrolled · United States
- Dec 2, 2022Phase 2 study in Aortic Valve StenosisNovartis · NCT05646381 · 502 planned · United States, Austria, Belgium and more
- Jun 2, 2023Phase 3 study in HyperlipoproteinemiasNovartis · NCT05900141 · 41 enrolled · Germany
- Feb 12, 2024Phase 3 study in Cardiovascular DiseasesNovartis · NCT06267560 · 422 enrolled · United States, Puerto Rico
- Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
- Mar 12, 2025Phase 3 study in AtherosclerosisNovartis · NCT06875973 · 599 enrolled · United States, Puerto Rico
- Apr 1, 2026Phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263 · 5,700 enrolled · United States, Argentina, Australia and more
- May 27, 2026Phase 3 study in Acute Coronary SyndromeNovartis · NCT07625306
- Oct 14, 2026Phase 3 study withdrawnStudy stoppedNCT07625306 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
- Oct 14, 2026Primary completion moved from 2028-12-07 to 2029-01-22Date moved laterphase 3 · +2 months · NCT07625306
- Nov 10, 2026Phase 3 study terminatedStudy stoppedNCT05900141 · “Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”
Ahead
- Feb 3, 2028Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06813911
- Jan 9, 2030Primary completion: phase 3 study in Cardiovascular DiseasesNovartis · NCT07517263
- Mar 12, 2030Primary completion: phase 2 study in Aortic Valve StenosisNovartis · NCT05646381
- Dec 8, 2030Primary completion: phase 3 study in AtherosclerosisNovartis · NCT06875973
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07625306Acute Coronary Syndrome | 3 | Withdrawn | Novartis | Jan 22, 2029 | 0 |
| NCT07517263Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Jan 9, 2030 | 5,700 |
| NCT06875973Atherosclerosis · United States, Puerto Rico | 3 | Active, not recruiting | Novartis | Dec 8, 2030 | 599 |
| NCT06813911Atherosclerosis · United States, China, France and more | 3 | Active, not recruiting | Novartis | Feb 3, 2028 | 246 |
| NCT06267560Cardiovascular Diseases · United States, Puerto Rico | 3 | Completed | Novartis | Mar 25, 2026 | 422 |
| NCT05900141Hyperlipoproteinemias · Germany | 3 | Terminated | Novartis | Oct 15, 2026 | 41 |
| NCT05646381Aortic Valve Stenosis · United States, Austria, Belgium and more | 2 | Recruiting | Novartis | Mar 12, 2030 | 502 |
| NCT05337878Healthy Participants · United States | 1 | Completed | Ionis Pharmaceuticals | Dec 18, 2019 | 29 |
| NCT05305664Cardiovascular Diseases · Germany | 3 | Completed | Novartis | Jan 28, 2025 | 51 |
| NCT05026996Hepatic Impairment · United States | 1 | Completed | Novartis | Oct 19, 2022 | 17 |
| NCT04023552Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Novartis | Jul 16, 2026 | 8,323 |
| NCT03506854Renal Insufficiency · United States, Canada | 1 | Completed | Ionis Pharmaceuticals | Oct 11, 2018 | 16 |
| NCT03426033Cardiovascular Diseases · Canada | 1 | Completed | Ionis Pharmaceuticals | Feb 25, 2018 | 18 |
| NCT03392051Cardiovascular Diseases · Canada | 1 | Completed | Ionis Pharmaceuticals | Mar 18, 2018 | 18 |
| NCT03070782Cardiovascular Diseases · United States, Canada, Denmark and more | 2 | Completed | Ionis Pharmaceuticals | Jul 26, 2018 | 286 |
| NCT02414594Elevated Lipoprotein(a) · Canada | 1 | Completed | Ionis Pharmaceuticals | Feb 2016 | 60 |
How it is read
Names in the registry
- “Pelacarsen”, 5 entries
- “ISIS 681257”, 4 entries
- “Pelacarsen (TQJ230)”, 2 entries
- “TQJ230”, 2 entries
- “Pelacarsen (TQJ230) 80 mg s.c.”, 1 entry
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 7 studies
- Atherosclerosis, 2 studies
- Hyperlipoproteinemias, 1 study
- Acute Coronary Syndrome, 1 study
- Aortic Valve Stenosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.